Routine share withholding; mechanical by default.
Traded Mar 11, 2026 · Filed Mar 12, 2026
BioMarin Pharmaceutical's Chief Technical Officer sold $997K of BioMarin Pharmaceutical shares. Nobody planned it ahead of time.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$996,744
Shares × reported transaction price
16 days after results of Feb 23, 2026, 54 days before results of May 4, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −7.5% | −2.1% | −5.4% |
| 30 days | −6.2% | +3.6% | −9.8% |
| 90 days | −5.1% | +11.4% | −16.5% |
| 180 days | +10.1% | +15.1% | −5.0% |
Past results only. Not a forecast.
Routine share withholding; mechanical by default.
Routine share withholding; mechanical by default.
Routine share withholding; mechanical by default.